Abstract
Preoperative chemotherapy combines appealing theoretical concepts of tumor biology and therapy, linking the postsurgical behavior of metastases with a potentially beneficial effect of the systemic chemotherapy given before the definitive surgery. There is evidence from experimental and some clinical studies indicating enhancement of cell kinetics after noncurative cytoreduction [8, 12–14, 2b, 53, 55]. According to some data, these changes are deleterious to the host, and a reduction of the survival was documented compared with animals without cytoreduction [12, 53]. Enhancement of the metastatic potential, and of the systemic spread of the residual clones, is suspected, and according to some data, may be improved by preoperative chemotherapy [5, 12]. Although preoperative chemotherapy has been used for several years routinely in head and neck tumors [16] and osteosarcomas [48], attempts at its implementation as a conceptually new approach have started recently for other tumors [15, 22, 42, 56] as seen from several international conventions on neoadjuvant therapy held over the last few years [22, 24, 42, 56].
Keywords
- Breast Cancer
- Advanced Breast Cancer
- Preoperative Chemotherapy
- Postoperative Chemotherapy
- Preoperative Treatment
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnold DJ, Lesnick GJ (1979) Survival following mastectomy for stage III breast cancer. Am J Surg 137: 362–6
Bonadonna G, Verennasi U, Brambilla C (1989) Primary CMF can avoid mastectomy in tumors more than 3 cms. Proc Am Soc Clin Oncol 8: 20
Chauvergne J, Durand M, Mauriac L et al. (1989) Randomized trial comparing mastectomy plus or minus adjuvant chemotherapy versus first line chemotherapy followed by adapted locoregional treatment for operable breast cancer. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 225–231
Clunet J (1910) Recherches expérimentales sur les tumeurs malignes. Steinhil, Paris
Corbett TH, Griswold DP Jr, Roberts BJ et al. (1981) Cytotoxic adjuvant therapy and the experimental model. In: Stoll BA (ed) Systemic therapy in breast cancer, vol 4. Heinemann Medical, London, pp 204–243
De Lena M, Varini M, Zucali R et al. (1981) Multi model treatment for locally advanced breast cancer. Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4: 229–236
De Lena M, Zucali R, Viganotti G et al. (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3B-T4) breast cancer. Cancer Chemother Pharmacol 1: 53–59
DeWys WD (1972) Studies correlating the growth rate of the tumor and its metastases and providing evidence for tumor related systemic growth retarding factors. Cancer Res 32: 374–379
Dressier L, Auclerc G, Owens M et al. (1987) DNA flow cytometry predicts for relapse in node negative breast cancer patients. Proc Am Soc Clin Oncol 6: 57
Emerman JT (1989) In vitro predictive sensitivity testing in the therapeutic assessment of breast cancer: In: Ragaz J, Ariel IM (eds) High risk breast cancer - Diagnosis. Springer Berlin Heidelberg New York, pp 345–362
Fisher B, Ravdin RG, Ausman RK et al. (1968) Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 168: 337–356
Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and the chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492
Fisher B, Gunduz N, Coyle J et al. (1989) Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 49: 1996–2002
Fisher B, Saffer E, Rudock C et al. (1989) Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 49: 2002–2005
Frei E III (1982) Clinical cancer research: an embattled species. Cancer 50: 1979–1992
Frei E III, Miller D, Clark JR et al. (1986) Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. In: Ragaz J, Band PR, Goldie JH (eds) Preoperative (neoadjuvant) chemotherapy. Springer, Berlin Heidelberg New York, pp 1–6
Freshney RI (1985) Induction of differentiation in neoplastic cells. Anticancer Res 5: 111–130
Hedley DW, Rugg CA, Ng ABP et al. (1984) Influence of cellular DNA content on disease free survival of stage II breast cancer patients. Cancer Res 44: 5395–5398
Hortobagyi GN, Blumenschein GR, Spanos W et al. (1983) Multimodal treatment of locally advanced breast cancer. Cancer 51: 763–768
Hortobagyi GN, Buzdar AU, Ames FC et al. (1989) Neoadjuvant chemotherapy in the management of advanced primary carcinoma of the breast. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy 2nd international congress. Libbey, Paris, pp 137–143
Hortobagyi GN, Frye D, Ames F et al. (1989) Quantitation of downstaging after neoadjuvant chemotherapy for primary breast cancer. Proc Am Soc Clin Oncol 8: 23
Jacquillat C, Weil M, Khayat D (eds) (1986) Neoadjuvant chemotherapy, 1st international congress. Libbey, Paris
Jacquillat C, Baillet F, Auclerc G et al. (1989) Preoperative (neoadjuvant) chemotherapy and radiotherapy in breast cancer. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 129– 137
Jacquillat C, Weil M, Khayat D (1989) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris
Kute TE, Muss HP, Hopkins N et al. (1985) Relationship of flow cytometry result to clinical and steroid receptor status in human breast cancer. Breast Cancer Res Treat 6: 113–121
Lange PH, Hekmat K, Bosl G et al. (1980) Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 45: 1498–1506
Le Riehe J, Atiba J, Ragaz J et al. (1989) The role of fine needle aspiration in determining the risk of breast cancer. In: Ragaz J, Ariel I (eds) High risk breast cancer-Diagnosis. Springer, Berlin Heidelberg New York, pp 120–137
Lesnick G, Perloff M, Korzun A et al. (1989) Neoadjuvant chemotherapy for stage III breast cancer - 5 year report of CALGB 7784. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 185–189
Lippman ME, Swain SM, Egan EF et al. (1989) Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 143–151
Ludvig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 319: 677–683
Ludvig Breast Cancer Study Group (1989) Prolonged disease free survival after one course of perioperative adjuvant chemotherapy for node negative breast cancer. N Engl J Med 320: 491–496
Morris DM, Aisner J, Elias EG et al. (1978) Mastectomy as an adjunct to combination chemotherapy. Arch Surg 113: 282–284
Nissen-Meyer R, Host H, Kjellgren K et al. (1987) Neoadjuvant chemotherapy in breast cancer as single perioperative treatment and with supplementary longterm chemotherapy. In: Salmon S (ed) Adjuvant therapy of cancer V. Grune and Stratton, Orlando, pp 253–263
Papaioannou AN (1981) Perspective in cancer research: preoperative chemotherapy for operable solid tumors. Eur J Cancer 17: 963–969
Papaioannou AN, Lissaios B, Vasilaros S et al. (1983) Pre and postoperative endocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer. Cancer 51: 1284–1290
Papaioannou AN, Polychronis A, Kozonis JA et al. (1986) Chemotherapy with or without anticoagulation as initial management of patients with operable colorectal cancer: a perspective study with at least 5 years followup. In: Ragaz J, Band PR, Goldie JH (eds) Preoperative (neoadjuvant) chemotherapy. Springer, New York, pp 142–148
Pierce GB, Speers WC (1988) Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48: 1996–2004
Preoperative Breast Protocol (1988) NSABP B18, 32nd semi-annual meeting, Washington, D.C.
Ragaz J, Baird R, Rebbeck P et al. (1985) Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 56: 719–724
Ragaz J (1986) Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy. NCI Monogr 1: 145–152
Ragaz J (1986) Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia trial. In: Ragaz J, Band P, Goldie J (eds) Preoperative (neoadjuvant) chemotherapy of cancer. Springer, Berlin Heidelberg New York, pp 85–94
Ragaz J, Band PR, Goldie JH (eds) (1986) Preoperative (neoadjuvant) chemotherapy. Springer, Berlin Heidelberg New York
Ragaz J, Manji M, Olivotto I et al. (1987) The role of mastectomy in preoperative (neoadjuvant) combined modality therapy of locally advanced breast cancer. Proc Am Soc Clin Oncol 6: 55
Ragaz J, Baird R, Goldie J (1989) Role of preoperative (neoadjuvant) therapy for breast cancer in stage I and II disease. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 157–169
Ragaz J, Manji M, Plenderleith IH et al. (1989) Analysis of the British Columbia study of preoperative (neoadjuvant) therapy of breast cancer in stage III disease. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 249–259
Reiss M, Gamba-Vitallo C, Sartorelli AC (1986) Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep 70: 201–218
Rocchi P, Ferreri AM, Simone G, Prod G (1987) Epirubicin induced differentiation of human neuroblastoma cells in vitro. Anticancer Res 7: 247–250
Rosen G (1986) Neoadjuvant chemotherapy for osteogenic sarcoma: a model for the treatment of other highly malignant neoplasms In: Ragaz J, Band PR, Goldie JH (eds) Preoperative (neoadjuvant) chemotherapy. Springer, Berlin Heidelberg New York, pp 148–158
Sachs L (1987) Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Res 47: 1981–1986
Sager Kern WH (1979) The diagnosis of breast cancer by fine needle aspiration smears. JAMA 241: 1125–1127
Salter DR, Bassett AA (1981) A role of fine needle aspiration in reducing the number of unnecessary breast biopsies. Can J Surg 24: 311–313
Schwartz EL, Sartorelli AC (1982) Structure activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res 42: 2651–2655
Simpson-Herren L, Sanford AH, Holmquist JP (1976) Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 60: 1749–1760
Thalmo W, Sand J, Marti J et al. (1984) Clinical and pathological findings in locally advanced breast cancer treated with Cyclophosphamide-Adriamycin-5-FU. Proc Am Soc Clin Oncol 3: 127
Tyzzer EE (1973) Factors in the production and growth of tumor metastases. J Med Res 28: 309
Wagener DJT, Blijham GH, Smeets JBE et al. (1985) Primary chemotherapy in cancer medicine. Liss, New York
Zajicek J (1974) Aspiration Biopsy and cytology pt.I: cytology of supradiaphragmatic organs. Karger, New York
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Ragaz, J. (1991). Role of Preoperative Therapy in High-Risk Breast Cancer: Review. In: Ragaz, J., Ariel, I.M. (eds) High-Risk Breast Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74728-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-74728-1_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74730-4
Online ISBN: 978-3-642-74728-1
eBook Packages: Springer Book Archive